RHINOMED 
The two-day OneMed event that begins today (US time) coincides with the 33rd Annual JP Morgan Healthcare Conference. The JP Morgan conference has now created a week of events in San Francisco which provides an opportunity for briefings from emerging companies, large pharmaceutical companies, public and private investors, analysts, bankers, industry professionals and US institutional investors.
Mr. Johnson will provide an update on the company's progress and plans for 2015. A presentation will be given at the Marriot Marquis at 11.40 (PST) today.
A copy of the presentation can be found on the Rhinomed website. www.rhinomed.global Media Enquiries
About Rhinomed Ltd:
Rhinomed Limited is a medical technology firm that focuses on nasal, respiratory and breathing management technologies. The company is monetising its technology portfolio in the Sport and recreation market, Sleep, Wellbeing and Drug delivery markets.
Rhinomed's technology is designed to radically improve the way you breathe sleep, maintain your health and take medication.
The first product brought to market is the Turbine(TM). A radical nasal technology that improves airflow by an average of 38%, the Turbine(TM) is an internal nasal dilator that has since it's launch in January 2014 in Australia, grown to be widely adopted by leading cyclists and triathletes globally.
Now shipped to over 36 countries and with a growing global distribution base, the Turbine(TM) is providing all those undertaking aerobic activities with an opportunity to breathe better, perform better and get more enjoyment from their sport and exercise.
Source:
Rhinomed Ltd
Contact:
Michael Johnson CEO & Managing Director +61 (03) 8416 0900 mjohnson@rhinomed.com.au Follow us on twitter @rhinomedceo
